Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143291 | 1.00 | PARP1 (0.50) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL4143287 | 1.00 | PARP1 (0.50) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL2392874 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL1742200 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL12373174 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL2392876 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL1746670 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL2392867 | 0.84 | PARP1 (0.52) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6786016 | 0.83 | PARP1 (0.50) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL21119276 | 0.80 | PARP1 (0.47) | PARP1L3MBTL1ALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2007114771-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007073284-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | PSEN2, APP, PSEN1 | PARP1 1068/4885L3MBTL1 3904/4885ALDH1A1 1092/4885 |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | PSEN2, PSEN1, MAPT | PARP1 91/4885L3MBTL1 3520/4885ALDH1A1 394/4885 |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | PARP1 3264/4885L3MBTL1 2589/4885ALDH1A1 2591/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | PARP1 749/4885L3MBTL1 3248/4885ALDH1A1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.